company background image
PNV logo

PolyNovo Informe acción ASX:PNV

Último precio

AU$2.07

Capitalización de mercado

AU$1.4b

7D

2.5%

1Y

50.5%

Actualizada

08 Nov, 2024

Datos

Finanzas de la empresa +

PolyNovo Limited

Informe acción ASX:PNV

Capitalización de mercado: AU$1.4b

Resumen de acción PNV

PolyNovo Limited diseña, fabrica y vende dispositivos médicos biodegradables en Estados Unidos, Australia, Nueva Zelanda y a escala internacional.

Análisis fundamental de PNV
Puntuación del snowflake
Valoración2/6
Crecimiento futuro5/6
Rendimiento pasado3/6
Salud financiera5/6
Dividendos0/6

Competidores de PolyNovo Limited

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de PolyNovo
Precios históricos de las acciones
Precio actual de la acciónAU$2.07
Máximo en las últimas 52 semanasAU$2.78
Mínimo de 52 semanasAU$1.30
Beta1.72
1Cambio en 1 mes-14.81%
Variación en 3 meses-14.81%
Cambio de 1 año50.55%
3Variación en 3 años37.09%
Variación en 5 años-6.33%
Variación desde la OPV935.00%

Noticias y actualizaciones recientes

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Oct 10
Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Recent updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Oct 10
Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Aug 28
PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Aug 06
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

May 08
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

When Should You Buy PolyNovo Limited (ASX:PNV)?

Feb 28
When Should You Buy PolyNovo Limited (ASX:PNV)?

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Feb 02
Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08
PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22
Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26
When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30
Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18
Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23
Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05
Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16
Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01
PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29
What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15
PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16
Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28
We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07
There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13
Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19
PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08
Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27
News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25
Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17
Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Rentabilidad de los accionistas

PNVAU Medical EquipmentMercado AU
7D2.5%2.0%0.7%
1Y50.5%13.8%16.7%

Rentabilidad vs. Industria: PNV superó a la industria Australian Medical Equipment, que obtuvo un rendimiento del 13.8% el año pasado.

Rentabilidad vs. Mercado: PNV superó al mercado Australian, que obtuvo un rendimiento del 16.7% el año pasado.

Volatilidad de los precios

Is PNV's price volatile compared to industry and market?
PNV volatility
PNV Average Weekly Movement6.1%
Medical Equipment Industry Average Movement9.8%
Market Average Movement8.5%
10% most volatile stocks in AU Market17.2%
10% least volatile stocks in AU Market3.5%

Precio estable de las acciones: PNV no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PNV (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
1998254Swami Raotepolynovo.com

PolyNovo Limited diseña, fabrica y vende dispositivos médicos biodegradables en Estados Unidos, Australia, Nueva Zelanda y a escala internacional. La empresa ofrece NovoSorb Biodegradable Temporising Matrix, un andamio dérmico para la regeneración de la dermis cuando se pierde por una cirugía extensa, un traumatismo o una quemadura. También desarrolla dispositivos para la reparación de hernias y soluciones para la reconstrucción de hernias ventrales y de la pared abdominal compleja; NovoSorb Dermal Beta Cell, un novedoso páncreas ectópico intracutáneo para tratar la diabetes de tipo 1; NovoSorb MTX para injertos de una sola fase en quemaduras, heridas crónicas y quirúrgicas; y productos para plásticos y dispositivos reconstructivos.

Resumen de fundamentos de PolyNovo Limited

¿Cómo se comparan los beneficios e ingresos de PolyNovo con su capitalización de mercado?
Estadísticas fundamentales de PNV
Capitalización bursátilAU$1.41b
Beneficios(TTM)AU$5.26m
Ingresos (TTM)AU$103.23m

271.8x

Ratio precio-beneficio (PE)

13.9x

Ratio precio-ventas (PS)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PNV
IngresosAU$103.23m
Coste de los ingresosAU$16.41m
Beneficio brutoAU$86.82m
Otros gastosAU$81.56m
BeneficiosAU$5.26m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)0.0076
Margen bruto84.11%
Margen de beneficio neto5.10%
Ratio deuda/patrimonio3.6%

¿Cómo se ha desempeñado PNV a largo plazo?

Ver rendimiento histórico y comparativa